Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs

Olema Pharmaceuticals, Inc.

OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.
Among 19 evaluable patients, 13 showed tumor shrinkage; 2 confirmed + 1 unconfirmed partial response.
Most common TRAEs: dysgeusia (81% any grade), anemia (38%; 6% grade 3), neutropenia (34%; 28% grade 3).
Dose-proportional PK; at ≥6 mg steady-state concentrations exceeded preclinical efficacy targets.
Data presented at ASCO May 30; also presenting OPERA-02 Phase 3 trial-in-progress poster.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.